Boehringer Ingelheim
FDA Grants Cyltezo Biosimilar ‘Interchangeable’ Status
The FDA has expanded the designation of adalimumab-adbm (Cyltezo, Boehringer Ingelheim) to include interchangeable ...
OCTOBER 19, 2021
FDA Approves New Indication for Gilotrif
Boehringer Ingelheim's Gilotrif gets a new indication for the first-line treatment of patients with metastatic ...
JANUARY 18, 2018
FDA Approves Cyltezo, Biosimilar of Humira
Second new adalimumab biosimilar approved for multiple indications.
AUGUST 28, 2017
Load more